TrialThe New England journal of medicine2019
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.
Alok A Khorana et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
337 papers cite itlatest 60 shown
this paperpooled ittrialcites it